Peregrine Pharmaceuticals reported $22.42M in Cost of Sales for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Agenus AGEN:US $ 543K 338K
Amgen AMGN:US $ 1561M 157M
AstraZeneca AZN:LN 2279M 790M
Biocryst Pharmaceuticals BCRX:US $ 0.24M 0.18M
Bristol Myers Squibb BMY:US $ 2471M 115M
ChemoCentryx CCXI:US 205K 97K
Eli Lilly And LLY:US $ 2072.1M 21.9M
GlaxoSmithKline GSK:LN 3645M 30M
Intrexon XON:US $ 17.1M 2.17M
Karyopharm Therapeutics KPTI:US $ 1.43M 684K
MacroGenics MGNX:US 48K 899K
Mannkind MNKD:US $ 11M 0.44M
Merk MRK:US $ 5334M 1507M
Novartis NOVN:VX SF 3755M 245M
Peregrine Pharmaceuticals PPHM:US $ 22.42M 5.5M
Repligen RGEN:US $ 82.36M 0.31M